Phase 3
Completed N=20
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
Source: ClinicalTrials.gov NCT00511810 ↗Enrolled (actual)
20
Serious AEs
10.0%
Results posted
Dec 2014
Primary outcomePrimary: Mood Symptoms Ratings — 33.0; 33.1 CDRS-R score
Summary
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mood Symptoms Ratings |
33.0; 33.1 | — |
Eligibility Criteria
Inclusion Criterion:
- Between the ages of 12-18 years.
- Diagnosis of MDD and not exhibited symptom remission CDRS-R (> 28 but 3).
- Hospitalized within the last 3 months
- Greater than 1 year outside appropriate age/grade level
- Pacemaker
- Cerebral aneurysm clip
- Cochlear implant
- Metal fragments lodged within the eye or braces
- Claustrophobia
- Necessity of sedation (no sedation will be given).
- History of loss of consciousness > 10 minutes in duration
- Allergy to seafood.
Data sourced from ClinicalTrials.gov (NCT00511810). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.